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Abstract
Background: In many countries, routine clinical anaesthesia does not always involve neuromuscular monitoring.
In these clinical settings, the efficacy and safety of sugammadex use has not yet been confirmed. We investigated
the efficacy and safety of sugammadex in the absence of neuromuscular monitoring.
Methods: One hundred and forty patients who underwent laryngeal microsurgery with the use of rocuronium
as a neuromuscular blocking agent, without the use of a neuromuscular monitoring device, were retrospectively
investigated. The patients were randomly chosen among all the patients who met the inclusion criteria at a tertiary
university hospital between July 2013 and February 2015 and were allocated to group S (sugammadex group) or group
P (pyridostigmine group) according to the neuromuscular reversal agent administered. Five patients were excluded
from analysis and 135 patients completed the study. Primary outcome was extubation time. Secondary outcomes were
anaesthesia time, the correlation between anaesthesia time and extubation time, the total amount of rocuronium, and
postoperative adverse events in the post-anaesthesia care unit (PACU).
Results: Extubation time was significantly shorter in group S (6.3 ± 3.9 min) than in group P (9.0 ± 5.4 min). Anaesthesia
time was also significantly shorter in group S (30.7 ± 10.3 min) than in group P (35.8 ± 12.6 min). In the patients with an
anaesthesia time of 30 min or less, there was a positive correlation between anaesthesia time and extubation time in
group P (r = 0.453), but there was no significant relationship in group S. The total amount of rocuronium used
was higher in group S (0.62 ± 0.11 mg kg−1) than in group P (0.38 ± 0.14 mg kg−1). Postoperative adverse events
in the PACU were comparable between the groups, except for tachycardia events: the incidence of tachycardia
was significantly lower in group S (8.0 %) than in group P (17.3 %).
Conclusions: Sugammadex could shorten anaesthesia and extubation times as well as recovery time in the PACU
and reduce postoperative hemodynamic complications in a clinical setting in the absence of neuromuscular monitoring.
This may enhance the patients’ recovery in the operating room and PACU while improving the postoperative condition
of patients.
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Background
The recommended dose of sugammadex ranges from 2 to
16 mg kg −1 and is based on an objective assessment of
the depth of the neuromuscular block [1]. Such assess-
ments require the aid of appropriate neuromuscular
monitoring devices. However, in Korea, routine clinical
anaesthesia does not usually involve neuromuscular
monitoring, because of lack of understanding of the
need for monitoring, or because anaesthesiologists are
not yet accustomed to such monitoring, or find it an
inconvenience. This is also not uncommon elsewhere
in the world [2–5]. In such clinical setting, the efficacy
and safety of sugammadex use has not yet been clearly
confirmed.
Sugammadex has been demonstrated to shorten the
time to reach a train-of-four ratio of 0.9 as well as the
extubation time, resulting in improvement of operating
room turnover in clinical anaesthesia settings, including
neuromuscular monitoring [6, 7]. Therefore, sugamma-
dex may be a useful factor for the enhanced recovery
after surgery (ERAS) protocol [8]. However, this view-
point has not yet been reported in a clinical setting in
the absence of neuromuscular monitoring.
Sugammadex may be recommended for the reversal
of neuromuscular block in surgery that requires deep
blockade to facilitate surgical procedures or that re-
quires very short surgical time [6]. From this point of
view, laryngeal microsurgery meets the indications for
sugammadex use. Therefore, we frequently use this agent
for the reversal of neuromuscular block in laryngeal
microsurgery, although we do not implement neuromus-
cular monitoring, including train-of-four monitoring, for
the process.
We therefore aimed to investigate whether sugamma-
dex shortens anaesthesia time, extubation time, and re-
covery time in the postoperative period, and to establish
whether it reduces postoperative adverse events, as com-
pared with pyridostigmine, one of the reversal agents
most commonly used in our hospital. In our hospital,
the administration of rocuronium and its reversal agent
is not guided by neuromuscular monitoring in patients
undergoing laryngeal microsurgery. We hypothesized
that sugammadex could shorten anaesthesia and extuba-
tion times, as well as the recovery time during the post-
operative period, and that it can reduce postoperative
haemodynamic complications in patients undergoing la-
ryngeal microsurgery, even in the absence of neuromus-
cular monitoring
Methods
Ethical approval for this study was provided by the Korea
University Guro Hospital Institutional Review Board,
Seoul, Republic of Korea on 31 January 2015 (approval
number: KUGH15105-002). The requirement for written
informed consent from the patients was waived by the
institutional review board because the design of this
study was a retrospective study. The trial was registered
in the UMIN clinical trials registry (unique trial number:
UMIN000016602; registration number: R000019266; prin-
cipal investigator’s name: Byung Gun Lim; date of registra-
tion: 22 February 2015).
Patient population, study protocol and data collection
One hundred and forty patients who underwent elective
laryngeal microsurgery with the use of rocuronium as
the intraoperative neuromuscular blocking agent, with-
out the use of an intraoperative neuromuscular monitor-
ing device, at the Korea University Guro Hospital from
July 2013 to February 2015 were retrospectively investi-
gated through the electronic medical record system. Pa-
tients were all American Society of Anaesthesiologists
(ASA) physical status I or II and aged 19–75 years. Since
the proper sample size calculated from the result of a
pilot study was 70 for each group, among all the patients
who met the inclusion criteria since the introduction of
sugammadex use at our hospital up to the initiation of
this study, 70 patients from those to whom sugammadex
was administered and 70 patients from those to whom
pyridostigmine was administered were chosen randomly
using a random integer generator program. Five patients
with unusually long operation time, due to difficulties in
performing either endotracheal intubation or the surgery,
were excluded, and a total of 135 patients were finally allo-
cated to group S (sugammadex group; n = 68) or group P
(pyridostigmine group; n = 67) according to the neuro-
muscular reversal agent that had been administered. The
dose of the neuromuscular reversal agent administered at
each group was as follows: The dose of sugammadex was
2.3 ± 0.5 mg kg−1 in group S and the dose of pyridostig-
mine was 10 mg in all patients in group P. All data,
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including patients’ characteristics, and primary and sec-
ondary outcomes, were collected from the electronic med-
ical record system by an investigator unaware of the
purpose of the study.
Study endpoints
The primary outcome was extubation time which was
measured as the time interval from the end of surgery to
extubation. Secondary outcomes were anaesthesia time,
the correlation between anaesthesia time (the time inter-
val from intubation to extubation) and extubation time
in patients with an anaesthesia time of 30 min or less,
the total amount of rocuronium and reversal agents
used, the number of patients in whom additional rocuro-
nium, beside the initial injection, was required during sur-
gery, the interval between the end of surgery and the
administration of reversal agents, the interval between the
administration of the last dose of rocuronium and the ad-
ministration of reversal agents, the time to reach a Ramsay
sedation score of 2 and the recovery time in the post-
anaesthesia care unit (PACU) (the time to reach a modified
Aldrete score of 10 from entering the PACU), and postop-
erative adverse events in PACU, including respiratory and
haemodynamic complications, postoperative residual
weakness, postoperative nausea and vomiting (PONV)
or pain (specifically, desaturation [SpO2 < 93 %], laryn-
gospasm [upper airway obstruction], tachypnea or apnea,
tachycardia or bradycardia, hypertension or hypotension,
severe PONV, or pain requiring anti-emetics or analgesics).
Tachycardia, bradycardia, hypertension, and hypotension
were considered positive if the values exceeded ± 20 % of
the pre-induction vital signs.
Sample size calculation
The primary endpoint in this study was extubation time.
The sample size calculation was based on the results of
extubation time from a pilot study involving 10 cases in
each group. In the pilot study, extubation times (mean ±
standard deviation) were 6.7 ± 3.9 min in group S and
9.5 ± 6.8 min in group P. Therefore, the effect size of a
2-group study was 0.5. On the assumption that the allo-
cation ratio was 1, and with a sample size of 63 for each
group, a power of 0.8 at a level of significance of 0.05
would be achieved (calculated by a two-sided Student’s
t-test). Considering a 10 % dropout rate, the sample size
for final enrolment was 70 in each group.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences, version 12.0 (SPSS, Chicago,
IL, USA). Categorical data, including sex, ASA class, op-
eration type, the number of patients given additional
rocuronium, and the incidence of postoperative adverse
events between the groups were compared using a chi-
squared test or Fisher’s exact test. Other parametric data,
including further demographic data, such as age, height
etc., anaesthesia time, extubation time, the total amount
of rocuronium injected, the time interval between the end
of surgery and the injection of reversal agents, the time
interval between the administration of the last dose of
rocuronium and the administration of reversal agents, the
time to reach a Ramsay sedation score of 2, and the recov-
ery time in the PACU were compared using a two-tailed
Student’s t-test (normally distributed data) or the Mann–
Whitney U-test (non-normally distributed data). The rela-
tion between anaesthesia time and extubation time in each
group was analyzed with Spearman Rank Order Correl-
ation analysis. A P-value < 0.05 was considered statistically
significant. We performed Bonferroni correction to reduce
the chances of obtaining false-positive results (type I er-
rors) when multiple pair wise tests are performed on a
single set of data in the statistical analysis of secondary
outcomes regarding time intervals which were partly
overlapping (the interval between the administration of
the last dose of rocuronium and the administration of
reversal agents vs. the interval between the end of sur-
gery and the administration of reversal agents, and the
time to reach a Ramsay sedation score of 2 vs. the re-
covery time in the PACU). In the analysis of these out-
comes, a P-value < 0.025 was considered statistically
significant.
Results
A total of 135 patients were evaluated, with 68 patients in-
cluded in group S and 67 patients in group P. The demo-
graphic and clinical data were not significantly different
between the groups (Table 1). Extubation time was signifi-
cantly (P = 0.002) shorter in group S (6.3 ± 3.9 min) than in
Table 1 Demographic and clinical data of patients
Variables Group S (n = 68) Group P (n = 67)
Age (years) 51.8 ± 12.9 52.9 ± 12.0
Sex (M/F) 45/23 46/21
Height (cm) 165.3 ± 8.2 165.3 ± 8.8
Weight (kg) 66.6 ± 12.2 66.9 ± 12.1





thiopental dose (mg kg−1)
1.9 ± 0.2 /
4.7 ± 0.3
1.84 ± 0.26 /
4.77 ± 0.48
Operation time (min) 9.6 ± 6.0 10.0 ± 7.0
Insp. SEVO/DES (vol %)
at the end of surgery
2.15 ± 0.55 /
6.16 ± 0.68
2.35 ± 0.6 /
6.04 ± 1.06
The patient data are presented as mean ± SD or number of patients. There
was no statistically significant difference between the groups for any of the
variables. Group S: patients who received sugammadex as a reversal agent.
Group P: patients who received pyridostigmine as a reversal agent
M male, F female, ASA American Society of Anaesthesiologists, Insp. Inspiratory,
SEVO Sevoflurane, DES Desflurane
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group P (9.0 ± 5.4 min). Anaesthesia time was also signifi-
cantly (P = 0.043) shorter in group S (30.7 ± 10.3 min) than
in group P (35.8 ± 12.6 min). In the patients with an an-
aesthesia time of 30 min or less (32 and 34 patients in
groups P and S, respectively), there was a positive correl-
ation between anaesthesia time and extubation time in
group P (r = 0.453; P = 0.01), but no significant relation-
ship in group S (r = 0.271; P = 0.12; Fig. 1). The total
amount of rocuronium used was higher in group S (0.62
± 0.11 mg kg−1) than in group P (0.38 ± 0.14 mg kg−1;
P ≤ 0.001). Patients in group P needed additional rocur-
onium during the surgery in more cases than did those
in group S (14 vs. 2, respectively; P = 0.003). Among sec-
ondary outcomes regarding time intervals, the time to
reach a Ramsay sedation score of 2, and the recovery time
in the PACU were significantly shorter in group S than in
group P (since every patient reached a modified Aldrete
score of 10 upon reaching a Ramsay sedation score of 2,
the times to reach these two criteria were the same). The
interval between the end of surgery and the administration
of reversal agents, and the interval between the adminis-
tration of the last dose of rocuronium and the administra-
tion of reversal agents were comparable between the
groups (Table 2).
Postoperative adverse events in the PACU were compar-
able between the groups, except for tachycardia events
(Table 3). The incidence of tachycardia was significantly
(P ≤ 0.001) lower in group S (8.0 %) than in group P
(17.3 %). There was one case with PONV who required
rescue antiemetics in group S and none in group P; this
was not statistically significant. The requirement for post-
operative analgesics was similar between the two groups
(five cases in group S, four cases in group P). There was
no desaturation (SpO2 < 93 %) event in group S, but there
was one such case in group P; this case did not fully re-
cover until 28 min after the initial rocuronium injection of
0.3 mg kg−1, which was 10 min after the injection of pyri-
dostigmine (10 mg) in the operating room. The patient
was moved to the PACU, intubated, and showed an SpO2
< 95 % even with a 6 L min−1 of O2 supply connected to
Fig. 1 The correlation between anaesthesia time and extubation time. In patients with an anaesthesia time of 30 min or less (32 and 34 patients
in groups P and S, respectively), there was a significant positive correlation between anaesthesia time and extubation time in group P (r = 0.453;
P = 0.01), but no significant correlation was seen in group S (r = 0.271; P = 0.12). Group P: patients who received pyridostigmine as a reversal
agent. Group S: patients who received sugammadex as a reversal agent
Park et al. BMC Anesthesiology  (2016) 16:48 Page 4 of 7
the endotracheal tube. The patient required a further
20 min in the PACU to recover to the point where extuba-
tion was possible. He was suspected to have postoperative
residual neuromuscular blockade. There was no laryngos-
pasm or apnea event in either group.
Discussion
Since its introduction, sugammadex showed marked effi-
cacy and safety, ringing in a new era of patient safety in
anaesthesiology [7]. However, since its dosing regimen ne-
cessitates the use of neuromuscular monitoring, the use of
this agent may be limited in certain situations, particularly
where such monitoring devices are not routinely used.
Several surveys have shown that this is not uncommon,
worldwide [2–5]. Hence, we here performed a retrospect-
ive study on the efficacy and safety of using sugammadex
in the absence of guidance provided by neuromuscular
monitoring. We considered that this study could show
whether sugammadex reduces anaesthesia and extubation
times, as well as recovery time in the PACU, facilitating
early recovery after surgery, even in the absence of neuro-
muscular monitoring, in a routine clinical anaesthesia set-
ting, without any intervention.
The results of the present study showed that sugam-
madex shortened anaesthesia time, extubation time, and
recovery time, without increasing the incidence of post-
operative adverse events. The effect of sugammadex in
shortening anaesthesia time, extubation time, and re-
covery time has been clearly demonstrated by many
previous studies performed around the globe in settings
using appropriate neuromuscular monitoring. The re-
sult of the present study further showed that the effi-
cacy of sugammadex remains firm, even in the absence
of proper neuromuscular monitoring [9–11].
Sugammadex not only enabled shorter extubation time
even with larger dose of rocuronium but also, though not
given at the dose guided by proper neuromuscular moni-
toring, reversed the neuromuscular block within relatively
constant time in our study. In group P, the extubation
time was longer and the variation in this time was larger.
There was a positive correlation between anaesthesia time
and extubation time in group P, but not in group S, which
indicated that extubation time in group P functioned as a
key component influencing the anaesthesia time, whereas
the relatively constant extubation time in group S was not
a main determinant of anaesthesia time, even in the ab-
sence of neuromuscular monitoring.
The shortened anaesthesia time, extubation time, and
recovery time in group S may allow faster operating
room turnover, and this can allow better patient progno-
sis in terms of overall safety and recovery. ERAS has re-
cently gained increasing attention. Enhanced recovery
protocols for perioperative care have been proven to re-
duce complications after surgery, improve overall out-
comes, and shorten the length of hospital stay, thus
saving on resources [12]. Thus, guidelines for specific
fields are being formulated and are being published
throughout the world [13–16]. According to the ERAS
protocol developed by the ERAS society, using short-
acting anesthetic agents is one of the elements compris-
ing the intraoperative component of the protocol [17].
Due to its ability to reverse rocuronium-induced neuro-
muscular blockade quickly, sugammadex combined with
rocuronium can work as a short-acting agent, even cap-
able of substituting for succinylcholine [18, 19]. Hence,
sugammadex combined with rocuronium can reduce an-
aesthesia time, recovery time, and length of hospital stay,
making it recommendable as a short-acting anesthetic
agent in the ERAS protocol [20, 21]. Based on the re-
sults of the present study, we strongly recommend use
of sugammadex combined with rocuronium even in a
clinical anaesthesia setting without neuromuscular mon-
itoring as a new element in the ERAS protocol.
Table 2 Secondary outcomes regarding time intervals measured








4.9 ± 3.2 6.8 ± 4.8 0.026
Reversal agent injection
interval 2b (min)
22.3 ± 8.3 25.7 ± 10.4 0.084
Recovery time in PACUc (min) 3.1 ± 5.3* 8.1 ± 9.0 ≤0.001
Time to reach Ramsay sedation
score 2 in PACU (min)
3.1 ± 5.3* 8.1 ± 9.0 ≤0.001
The patient data are presented as mean ± SD. Group S: patients who received
sugammadex as a reversal agent. Group P: patients who received
pyridostigmine as a reversal agent
PACU post-anaesthesia care unit
*P < 0.025 vs. group P (Bonferroni correction)
athe interval between the end of surgery and the administration of
reversal agents
bthe interval between the administration of the last dose of rocuronium and
the administration of reversal agents
cthe time to reach modified Aldrete score 10






PONV required to use rescue antiemetics (n) 1 None 0.994
Hypertension events (%) 3.0 2.9 0.977
Hypotension events (%) 4.1 6.4 0.17
Tachycardia events (%) 8.0* 17.3 ≤0.001
Bradycardia events (%) 7.8 10.7 0.156
Incomplete reversal case with hypoxia (n) None 1 0.994
The patient data are presented as number of patients (n) or incidence of
haemodynamic events (%). Group S: patients who received sugammadex
as a reversal agent. Group P: patients who received pyridostigmine as a
reversal agent
PACU post-anaesthesia care unit, PONV Postoperative nausea and vomiting
*P < 0.05 vs. group P
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As for the adverse events, although not statistically
significant, there was one case of incomplete reversal in
group P, which can cause detrimental complications,
whereas no such case was found in group S [22, 23]. As is
known from several previous studies and surveys, anaes-
thesiologists in our hospital tend also to use larger doses
of rocuronium to achieve a theoretical deeper blockade
when sugammadex is planned for use at the end of sur-
gery; although obtaining a deeper block in group S was
not proven by neuromuscular monitoring, this trend is
clearly reflected in our study, as the total amount of rocur-
onium used in group S was significantly larger than that
used in group P [24]. This trend for obtaining a theoretical
deeper block, associated with sugammadex in group S,
highlights another benefit of sugammadex, in that there
were only two cases that needed additional rocuronium
during the surgery in group S, whereas group P required
this in 14 cases. It can be assumed that additional rocuro-
nium was needed because of incomplete or insufficient
neuromuscular block, in order to achieve optimal surgical
conditions, resulting in the possibility of elongated anaes-
thesia time, a shorter time between the last injection of
rocuronium and the injection of the reversal agent, and a
consequently higher risk of incomplete reversal of neuro-
muscular block or recurarization [8, 25]. Postoperative
haemodynamic values were found to be better in group S,
and the incidence of tachycardia was less. Glycopyrrolate
injected along with pyridostigmine in order to block its
cholinergic adverse effects may explain the significantly
higher incidence of tachycardia in group P [26].
The limitation of this study is that it was a retrospect-
ive study. We plan a randomized controlled trial on this
subject, to further assess its implications for the ERAS
protocol and the possible use of sugammadex in com-
bination with rocuronium in the ERAS protocol, in the
near future.
Conclusions
Sugammadex could shorten anaesthesia and extubation
times, as well as the recovery time in the PACU, and re-
duce postoperative haemodynamic adverse events in a
clinical setting in the absence of neuromuscular monitor-
ing. This may enhance the patients’ recovery in the operat-
ing room and PACU while improving the postoperative
condition of patients and may enhance the ERAS protocol.
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